The synergistic application of the stearoyl-CoA desaturase 1 (SCD1) inhibitor aramchol alongside the deuterated sorafenib derivative donafenib has shown significant anti-tumor efficacy in p53-wild type HCC organoids [59]. This evidence concerns the gene TP53 and neoplasm.